Research programme: hyperpoxaluria gene therapy - Amsterdam Molecular Therapeutics

Drug Profile

Research programme: hyperpoxaluria gene therapy - Amsterdam Molecular Therapeutics

Alternative Names: AMT 030

Latest Information Update: 16 Jul 2012

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Amsterdam Molecular Therapeutics
  • Class Gene therapies
  • Mechanism of Action Alanine-glyoxylate transaminase stimulants; Gene transference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Hyperoxaluria

Most Recent Events

  • 18 Nov 2009 No development reported - Preclinical for Hyperoxaluria in Netherlands (Parenteral)
  • 24 Mar 2006 Preclinical trials in Hyperoxaluria in Netherlands (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top